ResearcherUniversity Hospital UlmNo recent work listed

Niklas Sturm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9219-0099; OpenAlex author ID A5009727335. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 2 papers

Papers 2

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. First author DOI 10.1159/000521631 ↗
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Co-author DOI 10.3390/cancers14010217 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Thomas Jens Ettrich · 2 shared papers, 2022 · strength 0.46
- Paper The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. DOI 10.3390/cancers14010217 ↗
- Paper Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. DOI 10.1159/000521631 ↗
Lukas Perkhofer · 2 shared papers, 2022 · strength 0.46
- Paper The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. DOI 10.3390/cancers14010217 ↗
- Paper Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. DOI 10.1159/000521631 ↗
Felix Jakob Hüttner · 1 shared paper, 2022 · strength 0.20
- Paper Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling. DOI 10.1159/000521631 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.